SCHEMBL12426437

SCHEMBL12426437

CN(C)C(=O)Oc1ccccc1CN1C=C(C(=O)NCCc2ccccc2)c2ccccc2C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.45
GAA P10253 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TAAR1 Q96RJ0 2/20 0.40
RAB9A P51151 6/20 0.39
NPC1 O15118 5/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
THRB P10828 2/20 0.38
LMNA P02545 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
MAPT P10636 1/20 0.38
LIPG Q9Y5X9 1/20 0.37
MCHR1 Q99705 1/20 0.36
CYP2D6 P10635 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12426436 0.80 ACHE (0.44) TSHRMEN1KMT2ATHRBALDH1A1
SCHEMBL12426444 0.76 TSHR (0.43) TSHRRAB9ANPC1SMN1; SMN2MAPT
SCHEMBL12426441 0.74 TSHR (0.41) TSHRMEN1KMT2ARAB9ANPC1
SCHEMBL12426440 0.70 TSHR (0.37) TSHRALDH1A1
SCHEMBL11488474 0.65 TSHR (0.51) TSHRMEN1KMT2ARAB9ANPC1
SCHEMBL12426459 0.63 ACHE (0.41) TSHRRAB9ANPC1LMNA
SCHEMBL14067662 0.62 SMN1; SMN2 (0.44) TSHRKMT2ARAB9ANPC1SMN1; SMN2
SCHEMBL12426433 0.62 TSHR (0.45) TSHRMEN1KMT2AALDH1A1
SCHEMBL2198922 0.61 TSHR (0.61) TSHRRAB9ANPC1LMNAALDH1A1
SCHEMBL29728586 0.61 NCEH1 (0.54) TSHRRAB9ANPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1868998-B1 NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS VFP THERAPIES (FR) 2016-05-25 EP disclosed
US-7977354-B2 Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents INSA ROUEN (FR) 2011-07-12 US disclosed
US-20090062279-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS INSA ROUEN (FR) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062279-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS NLN, SNCA, APP TSHR 4786/4885GAA 337/4885MEN1 1231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.